T. Yao

发表

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

T J Yao, C. Hudis, L. Norton, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5‐fluorouracil and levamisole after resection of high risk colon cancer

W. Enker, J. Bertino, L. Saltz, 1994, Cancer.

Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor.

L. Norton, H. Thaler, N. Onetto, 1995, Journal of the National Cancer Institute.

Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.

A. Houghton, P. Chapman, Philip S. Livingston, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

The effects of Flk-2/flt3 ligand as compared with c-kit ligand on short-term and long-term proliferation of CD34+ hematopoietic progenitors elicited from human fetal liver, umbilical cord blood, bone marrow, and mobilized peripheral blood.

S. Rafii, D. Hicklin, M. Moore, 1996, Journal of hematotherapy.

Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

C. Hudis, L. Norton, M. Moasser, 2001, Breast Cancer Research and Treatment.

A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.

C. Hudis, L. Norton, A. Seidman, 2006, Clinical breast cancer.

Human papillomavirus vaccine: What are women most concerned about?

H. Ngan, A. Cheung, K. Chan, 2012, The journal of obstetrics and gynaecology research.

Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).

L. Old, A. Cohen, S. Welt, 1997, Cancer research.

Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.

L. Norton, J. Crown, D. Lebwohl, 1993, Seminars in oncology.

The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis

S. Fan, J. Chiu, T. Yau, 2012, Cancer.

Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high‐dose chemotherapy plus granulocyte‐macrophage colony‐stimulating factor a randomized trial

L. Norton, R. Motzer, J. Crown, 1993 .

Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.

C. Hudis, L. Norton, J. Baselga, 1998, Cancer investigation.

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.

C. Hudis, L. Norton, J. Baselga, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Surgery for Melanoma Metastatic to the Gastrointestinal Tract

D. Coit, T. Yao, S. Agrawal, 1999, Annals of Surgical Oncology.

The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring.

T J Yao, H. Ngan, K K L Chan, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell.

E. Dmitrovsky, J. Baselga, V. Reuter, 1993, Oncogene.

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

L. Norton, J. Baselga, P. Francis, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

S. Fan, T. Yau, R. Poon, 2014, Gastroenterology.

Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study

Angela M. Liu, J. Luk, S. Fan, 2012, BMJ Open.

Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.

J. Gabrilove, S. Heimfeld, S. Nimer, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of semisynthetic paclitaxel in metastatic breast cancer.

G. Hortobagyi, C. Hudis, L. Norton, 1997, European journal of cancer.

Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma

J. Whang‐Peng, Y. Chao, Jang-Yang Chang, 2006, Cancer Chemotherapy and Pharmacology.

Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma

S. Lowe, L. Zender, J. Luk, 2009, Cancer.

Title Circulating miR-15 b and miR-130 b in serum as potential markers for detecting hepatocellular carcinoma : A retrospective cohort study

Angela M. Liu, J. Luk, S. Fan, 2022 .

Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.

L. Norton, J. Crown, M. Markman, 1994, Cancer research.

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

C. Hudis, J. Crown, A. Seidman, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

C. Hudis, J. Baselga, J. Crown, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxol and Recombinant Human Granulocyte Colony‐Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer

C. Hudis, L. Norton, S. Arbuck, 1993, Annals of the New York Academy of Sciences.

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.

S. Fan, T. Yau, R. Poon, 2011, The oncologist.

Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer.

L. Norton, M. Moore, F. Shapiro, 1994, Blood.

A phase I study of anti‐GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage‐colony stimulating factor in patients with metastatic melanoma

D. Scheinberg, A. Houghton, E. Riedel, 1995, Cancer.

The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization

S. Fan, R. Epstein, T. Yau, 2009, Cancer.

An exploratory study of frequent pain measurement in a cancer clinical trial

A. Seidman, R. Portenoy, T. Yao, 1996, Quality of Life Research.

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

C. Hudis, L. Norton, M. Theodoulou, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.

C. Hudis, C. Hudis, D. Fennelly, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).

S. Fan, J. Chiu, T. Yau, 2011, The oncologist.

The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis.

S. Fan, J. Chiu, R. Poon, 2011, Journal of Clinical Oncology.

Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.

C. Hudis, L. Norton, J. Crown, 1994, Oncology.

Timing of radiotherapy in the treatment of early-stage breast cancer.

C. Begg, L. Norton, B. McCormick, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of carboplatin and etoposide in metastatic breast cancer

C. Hudis, L. Norton, J. Crown, 1993, Cancer.

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

S. Fan, T. Yau, R. Poon, 2012, Investigational New Drugs.

The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery.

L. Norton, J. Yahalom, J. Petrek, 1996, The cancer journal from Scientific American.

Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.

A. Houghton, P. Chapman, Philip S. Livingston, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy

S. Fan, T. Yau, R. Poon, 2008, Cancer.

Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.

D. Scheinberg, T. Deblasio, J. Jurcic, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.

C. Kensil, Philip S. Livingston, D. Marciani, 1994, Vaccine.

Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.

L. Norton, M. Moynahan, A. Houghton, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum.

S M Larson, S. Larson, D. Niedzwiecki, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.

J. Crown, D. Lebwohl, A. Seidman, 1993, Journal of the National Cancer Institute. Monographs.

The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).

S. Fan, J. Chiu, T. Yau, 2011, The oncologist.